Ian Elliott Brown, M.D., Ph.D.
- Assistant Professor
In the setting of severe injury, tissue injury occurs not only as a direct result of the traumatic insult, but also as a result of a patient's own inflammatory responses. These responses are often beneficial and appropriate in some settings but can potentially become maladaptive in the setting of severe injury. An understanding of these responses may help us to effectively mitigate some of the maladaptive consequences of these responses in appropriate situations. We examine the nature of inflammatory responses initiated by the inflammation/coagulation axis during severe injury.
M.D., University of Chicago, Pritzker School of Medicine, Chicago IL 2007
Ph.D., Immunology, University of Chicago, Chicago IL 2005
B.S., Stanford University, Palo Alto CA 1997
General Surgery, UC San Francisco Medical Center, San Francisco CA 2007-2014
Trauma and Surgical Critical Care, UC Davis Medical Center, Sacramento CA 2014-2015
Honors and Awards
UCSF Azakie-Chesson Award for Compassion in Surgery, 2014
Select Recent Publications
Brown I, Bellevue O, Shawo A, Woldesemayat H, Lyo V, Rayikanti B, Lee M, Uzosike E, Kasravi S, Harris HW. Low dose cyclophosphamide improves survival in a murine treatment model of sepsis. Shock. 2015 Jan;43(1):92-8.
Kline J, Brown I, Zha Y, Blank C, Strickler C, Wouters H, Zhang L, Gajewski, TF. Homeostatic proliferation plus regulatory T cell depletion promotes potent rejection of B16 melanoma. Clinical Cancer Research, 2008 May 15;14(10):3156-67
Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF. T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase. Nature Immunology, 2006 Nov;7(11):1166-73.
Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. Journal of Immunology, 2006 Oct 1 177: (7):4521-9.
Velicu S, Han Y, Ulasov I, Brown IE, Andaloussi AE, Gajewski TF, Lesniak MS. Cross- priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. Journal of Neuroimmunology. 2006 May;174(1-2):74- 81.